哮喘
医学
环境卫生
公共卫生
贝叶斯概率
多级模型
梅德林
共病
流行病学
呼吸道疾病
贝叶斯分层建模
可信区间
贝叶斯定理
临床实习
分层数据库模型
呼吸系统
风险评估
哮喘管理
贝叶斯推理
重症监护医学
全球卫生
儿科
随机效应模型
多发病率
家庭医学
作者
Yixuan Liu,Jiayi Ge,Geyang Xu,Chengfei Cai,Depin Chen,Jingru Tian,Jun Xu
摘要
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease often associated with asthma and rhinitis. However, epidemiological evidence on these comorbidities remains fragmented and is largely limited to high-income countries. OBJECTIVES: To provide comprehensive global, regional and country-level estimates of the prevalence and odds ratios (ORs) of asthma, rhinitis and their subtypes among individuals with AD. METHODS: We systematically reviewed 278 studies retrieved from PubMed, Embase, Web of Science and CNKI (China National Knowledge Infrastructure). Standardized prevalence estimates and ORs were derived using a Bayesian hierarchical linear mixed-effects model. RESULTS: Among individuals with AD, the global prevalence estimate of asthma, rhinitis, allergic rhinitis, rhinoconjunctivitis, and coexisting asthma and rhinitis was 20.1% (ranging from 2.5% in Israel to 59.4% in India), 45.1% (ranging from 7.8% in Israel to 82.7% in India), 41.4% (ranging from 6.8% in Israel to 80.3% in India), 30.7% (ranging from 4.3% in Israel to 71.9% in India) and 10.4% (ranging from 1.1% in Israel to 40.8% in India), respectively. Estimates were higher when restricted to patients with AD diagnosed by dermatologists or physicians. The highest comorbid prevalence rates were found for India, Cuba, Finland and Puerto Rico. Compared with healthy control individuals, AD was associated with higher odds of asthma (OR 2.73; ranging from 1.59 in China to 6.64 in Ethiopia), rhinitis (OR 2.98; ranging from 1.73 in China to 7.23 in Ethiopia), allergic rhinitis (OR 2.42; ranging from 1.41 in China to 5.89 in Ethiopia), rhinoconjunctivitis (OR 4.21; ranging from 2.45 in China to 10.19 in Ethiopia), and coexisting asthma and rhinitis (OR 2.42; ranging from 1.41 in China to 5.89 in Ethiopia). CONCLUSIONS: This study provides the first globally standardized estimates of respiratory comorbidities in AD, and can inform clinical practice and public health policy.
科研通智能强力驱动
Strongly Powered by AbleSci AI